Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT03747380 Completed - Lung Cancer Clinical Trials

Pre-operative Inspiratory Muscle Training Program to Prevent Pulmonary Complications After Thoracic Surgery

CT0076
Start date: January 7, 2019
Phase: N/A
Study type: Interventional

Postoperative pulmonary complications are the most common complications after thoracic surgery. In the literature, pulmonary complications after thoracic surgery are present in more than 37.5% of patients. No study investigates the impact of preoperative inspiratory muscle exercises program on pulmonary complications after thoracic surgery.

NCT ID: NCT03729661 Completed - Breast Cancer Clinical Trials

Exploratory Study on Therapy for Breath Hold in Radiotherapy

Start date: April 18, 2019
Phase: N/A
Study type: Interventional

Due to breathing and other motions, tumours, such as breast and lung cancer, as well as their surrounding organs (e.g. the heart), move, which poses a challenge for radiotherapy treatment. Reducing or even stopping breathing, e.g. by irradiating during inspiration, is a way to decrease tumour and organ motion resulting in a reliable target coverage with smaller margins. These smaller margins can result in a better sparing of normal tissues. Furthermore, in some patients, during inspiration, the heart may move away from the target volume making it possible to better spare the heart. Finally, during inspiration, the lung volume is larger and the lung density is lower, which can lead to a lower dose to the surrounding normal lung tissue. Reduction of radiation dose to normal tissues leads to less radiation-induced toxicity. This makes treating breast and lung cancer patients in breath hold (BH) conditions an attractive strategy. Standard BH durations in RT treatment are around 20 seconds, which is not enough to perform a complete CBCT. The health status of lung cancer patients is generally worse compared to breast cancer patients, making it more difficult to treat this patient group during breath hold. Nasal High Flow Therapy (NHFT) is a non-invasive system that provides controlled oxygen concentrations and low levels of positive pressure via a nasal interface. NHFT improves oxygenation in diverse patient groups, and is increasingly used as an alternative to mechanical ventilatory support. It has been shown to be a safe device in several clinical situations and patient populations, such as COPD patients, but also in apneic conditions under general anesthesia.

NCT ID: NCT03704870 Completed - Lung Cancer Clinical Trials

Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection

Start date: January 26, 2018
Phase: Phase 2
Study type: Interventional

Currently, it is the standard of care practice to perform daily routine CXR when a chest tube is in situ following pulmonary resection. However, previous research as well as experience of thoracic surgeons suggested this kind of management has poor diagnostic and therapeutic value. Eliminating daily routine CXR for adult patients having undergone pulmonary surgery might decrease the frequency of radiation exposure and hospitalization costs per patient without increasing reintervention rates, length of hospital stays, readmission rates or any adverse events.

NCT ID: NCT03694054 Completed - Lung Cancer Clinical Trials

Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers

Start date: June 4, 2018
Phase: N/A
Study type: Interventional

The Oncology Care Coordination study is designed to evaluate use of a care coordination tool for lung cancer patients and their caregiver on quality of care and performance outcomes. Eligible patients need to be receiving treatment at Geisinger. Participation in the study involves completion of surveys, permission to review information from the patient's electronic health record, and for some enrollment in the care coordination tool called Harmonized Care. Geisinger oncology care providers who have patients enrolled the study will be invited for interviews.

NCT ID: NCT03688347 Completed - Cancer Clinical Trials

Microbiome in Lung Cancer and Other Malignancies

Start date: August 30, 2018
Phase:
Study type: Observational

To characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.

NCT ID: NCT03683940 Completed - Lung Cancer Clinical Trials

Pilot Study of High Risk Lung Cancer Screening

Start date: August 10, 2016
Phase: N/A
Study type: Interventional

This study is a prospective trial of 200 individuals at high risk for lung cancer who are not eligible for lung cancer screening under current screening guidelines.

NCT ID: NCT03665285 Completed - Breast Cancer Clinical Trials

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Start date: October 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

NCT ID: NCT03662204 Completed - Breast Cancer Clinical Trials

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Start date: August 23, 2018
Phase:
Study type: Observational

The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.

NCT ID: NCT03661801 Completed - Lung Cancer Clinical Trials

Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions

INVEST
Start date: October 26, 2017
Phase:
Study type: Observational

The purpose of this study is to prospectively asses established biomarkers in the diagnosis and prognosis of patients and will include assessment of a number of biomarkers, genomics and proteomics.

NCT ID: NCT03658083 Completed - Lung Cancer Clinical Trials

Exploring Robotic-assisted Thoracic Surgery for Lung Cancer

ROSE
Start date: October 12, 2017
Phase:
Study type: Observational

Background Surgery for lung cancer can be performed using open (thoracotomy) or minimally invasive techniques (Video Assisted Thoracic Surgery (VATS)). Despite being associated with fewer postoperative complications (PPCs) VATS is difficult to perform and is only used by 20-44% of thoracic surgeons in the UK. Robotic-Assisted Thoracic Surgery (RATS) maybe a more attractive minimally invasive approach. To date, no studies have explored the impact of RATS on exercise capacity or physical activity and although 1 study has looked at Heath Related Quality of Life (HRQOL) post-RATS compared to an open technique indicators of surgical technique were not controlled for. Furthermore, investigators have little understanding of patients' experience of RATS. Aims 1. To examine the variability of change in exercise capacity and health-related quality of life (HRQOL) between those who receive thoracotomy V RATS. 2. To compare the difference in post-operative physical activity (step and activity count), across 7 days, in those who receive thoracotomy V RATS. 3. To explore the manner in which patients appraise their experience of undergoing RATS. Methods: A mixed-method, multi-center study will be undertaken, utilizing a prospective quasi-experimental study design and an interpretive phenomenological approach. 80 individuals, referred for a lung lobectomy with a primary or secondary diagnosis of lung cancer, will complete outcomes assessed at 4 time-points. The Incremental Shuttle Walk Test (ISWT) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30) and the EORTC Lung Cancer module (EORTC QLQ LC13) will be completed at: baseline, 3-6 days post surgery, 6-weeks post-surgery and at 3-month follow up. Patients will wear an activity monitor immediately post-surgery until 1-week post-discharge. Step and activity counts will be recorded. In-depth interviews will be conducted with up to 15 patients who underwent RATS to explore the manner in which patients appraise their experience of RATS.